Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

9. Check if this filing amends a previously filed version of this report

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code BUD

16. Specific lobbying issues

FY 2026 Appropriations for Agencies
---Administration for Strategic Preparedness and Response (ASPR)
---Biomedical Advanced Research and Development Authority (BARDA)
---Centers for Disease Control and Prevention
---Centers for Medicare and Medicaid Services (CMS)
---Food & Drug Administration (FDA)
---Health Resources and Services Administration (HRSA)
---HHS Office of Infectious Disease and HIV/AIDS Policy
---National Institutes of Health (NIH)

FY 2026 Appropriations for Specific Issues
---Antimicrobial Resistance (General)
---Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement
---CMMI Models: GLOBE and GUARD
---Funding for Section 317
---Funding for Strategic National Stockpile
---Pandemic Preparedness
---Reauthorization of Pandemic and All-Hazards Preparedness and Advancing (PAHPA)
---Vaccine Access & Compensation
---Pediatric Priority Review Voucher

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), Office of Management & Budget (OMB)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code CPT

16. Specific lobbying issues

Antitrust Legislation
---Oversight Pharmacy Benefit Managers

Artificial Intelligence (AI)

Bayh-Dole Act/Tech Transfer
---Bayh-Dole Act

Compulsory Licensing
---28 U.S.C. 1498 - Patent and copyright cases

Data Privacy
---Data Privacy Working Group Draft
---Implementation of BIOSECURE Act

Drug Patenting
---H.R.3160/S.1553: PREVAIL Act
---H.R.3269/S.2276: Eliminating Thickets to Increase Competition (ETHIC) Act
---S.43/H.R.6485: Skinny Labels, Big Savings Act
---S.527: Prescription Pricing for the People Act
---S.1041: Affordable Prescriptions for Patients Act
---S.1096: Preserve Access to Affordable Generics and Biosimilars Act
---S.1097: Interagency Patent Coordination and Improvement Act of 2025
---Patent Tax/fees
---Restrictions on Intellectual Property Rights

Foreign Drug Data Protection Law
---Implementation of BIOSECURE Act

Patent Reform
---H.R.3160/S.1553: PREVAIL Act
---S.1097: Interagency Patent Coordination and Improvement Act
---S.1546/H.R.3152: Patent Eligibility Restoration Act (PERA)
---PTAB Reform

Patenting of Biological Inventions
---S.1546/H.R.3152: Patent Eligibility Restoration Act (PERA)
---Section 101 Modernization

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code HCR

16. Specific lobbying issues

FY 2026 Appropriations for Agencies
---Administration for Strategic Preparedness and Response (ASPR)
---Biomedical Advanced Research and Development Authority (BARDA)
---Centers for Disease Control and Prevention
---Centers for Medicare and Medicaid (CMS)
---Food & Drug Administration (FDA)
---Health Resources and Services Administration (HRSA)
---HHS Office of Infectious Disease and HIV/AIDS Policy
---National Institutes of Health (NIH)

FY 2026 Appropriations for Specific Issues
---H.R.1262/S.932: Mikaela Naylon Give Kids A Chance Act
---Alternative Funding Programs
---Antimicrobial Resistance (General)
---Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement
---CICP
---CMMI: GLOBE and GUARD Models
---Drug Pricing
---Funding for Strategic National Stockpile
---Funding for Women's Health Research
---Implementation of the Inflation Reduction Act (IRA)
---Influenza Planning & Response
---MCM PRV Reauthorization
---Pandemic Preparedness -R&D Funding for Medical Countermeasures
---Pediatric Priority Review Voucher
---Prescription Drug User Fee Act (PDUFA) VIII Implementation
---Project Bioshield
---Reauthorization of Pandemic and All-Hazards Preparedness and Advancing (PAHPA)
---Section 317 Immunization Program
---Vaccines and Infectious Diseases
---Vaccine Injury Compensation Program

340B Drug Discount Program
---340B Rebate Rule
---Program Implementation & Oversight

Accelerated Approval

Artificial Intelligence (AI)

Alternative Funding Programs

Biodefense Research, Development and Procurement Issues (Non-Funding)
---Disease X Act
---Gain of function (Viral Gain of Function Research Moratorium Act, SAFE Risky Research Act)
---Implementation of BIOSECURE Act
---MCM PRV Program Reauthorization
---National Defense Authorization Act 2027
---Reauthorization of Pandemic and All-Hazards Preparedness and Advancing (PAHPA)
---Risky Research Review Act
---VICP Loopholes
---White House National Biodefense Strategy
---WHO Pandemic Preparedness Accord

Biosimilars
---Biosimilars Competition (General)
---Biosimilar Red Tape Elimination Act
---Interchangeability and Pharmacy Substitution
---Purple Book Draft Legislation
---Reimbursement

Cell & Gene Therapy
---H.R.1672: Maintaining Investments and New Innovation (MINI) Act

Clinical Trial Data in China

Data Privacy
---American Privacy Rights Act
---Clinical Trial Data in China
---Consumer Data Privacy and Security Act (Draft)
---Data Privacy Working Group Draft
---Implementation of BIOSECURE Act

Diagnostics and Personalized Medicine Regulation and Oversight

Diversity & Inclusion
---Decentralized Clinical Trials

Drug Evaluation and Review
---FDA Hiring Flexibility
---Promising Pathway Act
---PDUFA VII Implementation
---PDUFA VIII Negotiations

Drug Importation

Drug Manufacturing, Quality & Distribution
---Advanced Manufacturing
---Compounding Pharmacies
---Drug Shortages
---Supply Chain Integrity and Traceability
---Contract Manufacturing Ecosystem in the United States

Drug Patenting
---H.R.3269/S.2276: Eliminating Thickets to Increase Competition (ETHIC) Act
---H.R.6485/S.43: Skinny Labels, Big Savings Act
---S.527: Prescription Pricing for the People Act
---S.1095: Stop STALLING Act
---S.1041: Affordable Prescriptions for Patients Act
---S.1096: Preserve Access to Affordable Generics and Biosimilars Act
---S.1097: Interagency Patent Coordination and Improvement Act
---S.2658: Medication Affordability and Patient Integrity Act
---Ensuring Access to Generic Medications Act

Drug Pricing
---H.R.1672: Maintaining Investments and New Innovation (MINI) Act
---H.R.6166: Lowering Drug Costs for American Families Act
---S.526: Pharmacy Benefit Manager Transparency Act
---S.527: Prescription Pricing for the People Act
---S.832: Ensuring Pathways to Innovative Cures (EPIC) Act
---H.R. 5391/S. 2764 Protecting Patient Access to Cancer and Complex Therapies Act
---S.1095: Stop STALLING Act
---S.1096: Preserve Access to Affordable Generics and Biosimilars Act
---S.1302: Increasing Transparency in Generic Drug Application
---Access to Innovative Treatments Act
---Biosimilar Red Tape Elimination Act
---CMMI: GLOBE and GUARD Models
---CMMI Authority
---DRUG Act
---Ensuring Access to Generic Medications Act
---Ensuring Timely Access to Generics
---Implementation of the Inflation Reduction Act (IRA) of 2022
---Implementation of ORPHAN Cures Act
---International Pricing Policies
---Medicare Drug Price Negotiation Act
---Modernizing and Ensuring PBM Accountability (MEPA) Act
---National Coverage Determination
---Most Favored Nation Drug Pricing Proposals
---Patient Cost-Sharing and Implementation
---Tariffs

Efforts to Expand the Bio Economy & Bio Manufacturing

Foreign Drug Data Protection Law
---Implementation of BIOSECURE Act

Generic Drug Entry
---H.R.6485/S.43: Skinny Labels, Big Savings Act
---S.1095: Stop STALLING Act
---S.1302: Increasing Transparency in Generic Drug Applications Act
---Generic Drug Application Review Reforms
---Incentives for Generic Entry

Issues Relating to Medical Research and Animal Testing
---FDA Modernization Act 3.0

Medicaid
---S.526: Pharmacy Benefit Manager Transparency Act of 2025
---Average Manufacturer Price Calculations
---CMMI (GENEROUS Model)
---CMMI: GLOBE and GUARD Models
---Drug Benefit Design
---International Pricing Policies
---Medicaid VBPs for Patients (MVP) Act
---Modernizing and Ensuring PBM Accountability (MEPA) Act
---Most Favored Nation Drug Pricing Proposals
---Pricing and Rebates
---Alternative Payment Arrangements for Gene Therapies

National Defense
---Medical Countermeasure Priority Review Voucher Reauthorization
---National Defense Authorization Act of 2027

National Security
---S.3741: Biosecurity Modernization and Innovation Act of 2026
---Clinical Trial Data in China
---CMMI: GLOBE and GUARD Models
---Implementation of BIOSECURE Act
---International Pricing Policies
---Medical Countermeasure Priority Review Voucher Reauthorization
---NSC/OSTP priorities
---Nucleic acid synthesis security and biotechnology governance
---Most Favored Nation Drug Pricing Proposals

Opioid Crisis
---Coverage and Reimbursement
---Non-Opioid Analgesics

Orphan Drug Issues
---H.R.1262/S.932: Mikaela Naylon Give Kids a Chance Act
---S.705: Innovation in Pediatric Drugs Act of 2025
---Implementation of ORPHAN Cures Act
---Implementation of the Inflation Reduction Act (IRA) of 2022
---Orphan Drug Tax Credit
---Retaining Access and Restoring Exclusivity (RARE) Act
---Pediatric Priority Review Voucher

Pandemic Preparedness
---Drug Supply Chain Management
---R&D Funding for Medical Countermeasures
---Supply Chain Issues
---WHO Pandemic Preparedness Accord

Precision Medicine Initiative

Rare Pediatric Disease Priority Review
---H.R.1262/S.932: Mikaela Naylon Give Kids a Chance Act
---Pediatric Priority Review Voucher
---Rare Disease Pilot Program

Reimbursement and Coverage of Innovative Products
---H.R.6166: Lowering Drug Costs for American Families Act
---S.864/H.R.6423: HELP Copays Act
---Access to Innovative Treatments
---340B Rebate Rule
---CMMI Authority
---Implementation of the Inflation Reduction Act (IRA) of 2022
---Medicaid VBPs for Patients (MVP) Act
---Medicare Drug Price Negotiation Act
---Medicare Part B Physician-Administered Products
---National Coverage Determination
---Patient Cost-Sharing and Smoothing
---SAFE STEP Act
---Step Therapy
---Support of Patient Premiums and Cost-Sharing Obligations
---Value-Based Contracting and Communications

Vaccines and Infectious Diseases
---Adult Immunization
---Let Injured Americans Be Legally Empowered (LIABLE) Act
---Mandating Exclusive Review of Individual Treatments (MERIT) Act
---Maternal Immunization
---MCM Manufacturing & Capacity
---MCM R&D Incentives
---National Coverage Determination
---PASTEUR ACT
---SAFE STEP Act
---Vaccine Access Improvement Act
---Vaccine and Antimicrobial Resistance Product Development and Incentives
---Vaccine Injury Compensation Modernization Act
---Vaccine Injury Compensation Program
---Vaccine Quality Measure
---Vaccine Safety
---Vaccine Safety Net and Vaccine Infrastructure
---Value of Vaccines and Vaccine Confidence

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), Commerce - Dept of (DOC), White House Office, Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), Office of Science & Technology Policy (OSTP), Office of the Vice President of the United States, Office of Management & Budget (OMB), Natl Security Council (NSC), U.S. Trade Representative (USTR), Energy - Dept of, Patent & Trademark Office (PTO)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code HOM

16. Specific lobbying issues

FY 2026 Appropriations for Agencies
---Administration for Strategic Preparedness and Response (ASPR)
---Biomedical Advanced Research and Development Authority (BARDA)
---Centers for Disease Control and Prevention Vaccine Programs
---Health Resources and Services Administration (HRSA)
---HHS Office of Infectious Disease and HIV/AIDS Policy

FY 2026 Appropriations for Specific Issues
---Antimicrobial Resistance (General)
---Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement
---Funding for Strategic National Stockpile
---Funding for Women's Health Research
---Medical Countermeasure Priority Review Voucher Reauthorization
---Pandemic Preparedness -R&D Funding for Medical Countermeasures
---VICP/CICP

Biodefense Research, Development and Procurement Issues
---Executive Order on Withdrawing the United States from the World Health Organization
---Implementation of BIOSECURE Act
---Medical Countermeasure Priority Review Voucher Reauthorization
---National Defense Authorization Act 2027
---Reauthorization of Pandemic and All-Hazards Preparedness and Advancing (PAHPA)
---Risky Research Review Act
---State Strategic Stockpile Act
---WHO Pandemic Preparedness Accord

Pandemic Preparedness
---Drug Supply Chain Management
---Medical Countermeasure Priority Review Voucher Reauthorization
---Supply Chain Issues
---Medical Countermeasure Priority Review Voucher Reauthorization

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), Commerce - Dept of (DOC), Office of Science & Technology Policy (OSTP), Office of the Vice President of the United States, Natl Security Council (NSC)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code MED

16. Specific lobbying issues

FY 2026 Appropriations for Agencies
---Administration for Strategic Preparedness and Response (ASPR)
---Biomedical Advanced Research and Development Authority (BARDA)
---Centers for Disease Control and Prevention
---Food & Drug Administration (FDA)
---Health Resources and Services Administration (HRSA)
---HHS Office of Infectious Disease and HIV/AIDS Policy

FY 2026 Appropriations for Specific Issues
---Antimicrobial Resistance (General)
---Advanced Research Projects Agency for Health (ARPA-H) Act
---Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement
---Funding for Medical Countermeasures
---Funding for Section 317
---Funding for Strategic National Stockpile
---Implementation of the Inflation Reduction Act (IRA) of 2022
---MCM PRV Reauthorization
---Pandemic Flu
---Pandemic Preparedness - R&D Funding for Medical Countermeasures
---Reauthorization of Pandemic and All-Hazards Preparedness and Advancing (PAHPA)
---VICP/CICP

Antimicrobial Resistance

Biodefense Research, Development and Procurement Issues
---Medical Countermeasure Priority Review Voucher Reauthorization

CDC Reform

Pandemic Preparedness
---Medical Countermeasure Priority Review Voucher Reauthorization
---R&D Funding for Medical Countermeasures

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), Office of Management & Budget (OMB)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code MMM

16. Specific lobbying issues

FY 2026 Appropriations for Specific Issues
---Alternative Funding Programs
---Antimicrobial Resistance (General)
---CMMI: GLOBE and GUARD Models
---Drug Pricing
---Pandemic Preparedness - R&D Funding for Medical Countermeasures
---Vaccines and Infectious Diseases

340B Drug Discount Program
---340B Rebate Rule
---Executive Order on Access to Affordable Life-Saving Medications
---PROTECT 340B Act
---SUSTAIN 340B Act

Accelerated Approval

Antimicrobial Resistance

Artificial Intelligence (AI)

Alternative Funding Programs

Biosimilars
---Biosimilars Competition (General)
---Biosimilar Copay
---Biosimilars Red Tape Elimination Act
---Interchangeability and Pharmacy Substitution

Cell & Gene Therapy

Clinical Trial Data in China

Data Privacy
---Data Privacy Working Group Draft

Drug Evaluation and Review
---FDA Hiring Staffing

Drug Importation

Drug Manufacturing, Quality & Distribution
---Advanced Manufacturing
---Compounded Medicines
---Drug Shortages
---Supply Chain Integrity and Traceability

Drug Patenting
---H.R.3269/S.2276: Eliminating Thickets to Increase Competition (ETHIC) Act
---S.43/H.R.6485: Skinny Labels, Big Savings Act
---S.527: Prescription Pricing for the People Act
---S.1096: Preserve Access to Affordable Generics and Biosimilars Act
---S.1097: Interagency Patent Coordination and Improvement Act
---Restrictions on Intellectual Property Rights

Drug Pricing
---H.R.1492: Ensuring Pathways to Innovative Cures (EPIC) Act
---H.R.1672: Maintaining Investments and New Innovation (MINI) Act
---H.R.6166: Lowering Drug Costs for American Families Act
---S.526: Pharmacy Benefit Manager Transparency Act
---S.527: Prescription Pricing for the People Act
---S.1095: Stop STALLING Act
---S.1096: Preserve Access to Affordable Generics and Biosimilars Act
---S.1097: Interagency Patent Coordination and Improvement Act
---CMMI: GLOBE and GUARD Models
---CMMI Authority
---COVID-19 Pricing Related Provisions
---Implementation of ORPHAN Cures Act
---Implementation of the Inflation Reduction Act (IRA) of 2022
---International Pricing Policies
---Most Favored Nation Drug Pricing Proposals
---Patient Cost-Sharing and Implementation
---PBM Reform
---Strengthening Innovation in Medicare and Medicaid Act
---Tariffs

Foreign Drug Data Protection Laws

Medicaid
---S.526: Pharmacy Benefit Manager Transparency Act
---Alternative Payment Arrangements for Gene Therapies
---Average Manufacturer Price Calculations
---CMMI (GENEROUS Model)
---CMMI: GLOBE and GUARD Models
---Coverage of Accelerated Approval Products
---Drug Benefit Design
---Encouraging Innovation Benefit Design to Lower Costs for Seniors Act
---International Pricing Policies
---Medicaid Drug Rebate Program
---Most Favored Nation in Medicaid
---Pricing and Rebates
---Value-Based Purchasing (VBP) Rule

National Defense
---National Defense Authorization Act of 2027
---NSCEB Recommendations

Opioid Crisis
---Non-Opioid Analgesics

Orphan Drug Issues
---H.R.1262/S.932: Mikaela Naylon Give Kids A Chance Act
---H.R.6166: Lowering Drug Costs for American Families Act
---Implementation of ORPHAN Cures Act
---Implementation of the Inflation Reduction Act (IRA) of 2022
---Orphan Drug Tax Credit
---Pediatric Priority Review Voucher

Pandemic Preparedness
---Drug Supply Chain Management
---Medical Countermeasure Priority Review Voucher Reauthorization
---R&D Funding for Medical Countermeasures
---Supply Chain Issues

Precision Medicine Initiative

Reimbursement and Coverage of Innovative Products
---H.R.6166: Lowering Drug Costs for American Families Act
---S.864/H.R.6423: HELP Copays Act
---340B Rebate Rule
---CMMI Authority
---National Coverage Determination
---Support of Patient Premiums and Cost-Sharing Obligations
---Value-based Contracting and Communications
---H.R.5391/S.2764: Protecting Patient Access to Cancer and Complex Therapies Act

Vaccines and Infectious Diseases
---Adult Immunization
---Countermeasures Injury Compensation Program
---MCM Manufacturing & Capacity
---Medical Countermeasure Priority Review Voucher Reauthorization
---National Coverage Determination
---Vaccine Injury Compensation Program
---Vaccine Safety and Quality
---Vaccine Safety Net and Vaccine Infrastructure
---Value of Vaccines and Vaccine Confidence

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Commerce - Dept of (DOC), Food & Drug Administration (FDA), Office of the Vice President of the United States, Centers For Medicare and Medicaid Services (CMS), Natl Security Council (NSC), Office of Science & Technology Policy (OSTP), U.S. Trade Representative (USTR), Patent & Trademark Office (PTO), Office of Management & Budget (OMB)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code SMB

16. Specific lobbying issues

Capital Formation Incentives
---H.R.3323: Helping Startups Continue To Grow Act
---H.R.3339: Equal Opportunity for All Investors Act of 2025
---H.R.3348: Accredited Investor Definition Review Act
---H.R.3382/S.2924: Small Entity Update Act
---H.R.3394: Fair Investment Opportunities for Professional Experts Act

Capital Market Enhancements
---Accredited Investor Definition
---Public Float Threshold Update

Small Business Innovation Research (SBIR) Program
---H.R.3169/S.1573: SBIR/STTR Reauthorization Act of 2025
---H.R.4777: INNOVATE Act
---H.R.5100: To extend the SBIR and STTR programs, and for other purposes.
---S.3971: Small Business Innovation and Economic Security Act

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Small Business Administration (SBA), Natl Institutes of Health (NIH)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code TAX

16. Specific lobbying issues

FY 2026 Appropriations for Specific Issues
---Vaccines and Infectious Diseases
---VICP/CICP

Capital Formation Incentives
---American Innovation and Jobs Act

Incentives for Domestics Manufacturing

Orphan Drug Issues
---H.R.1262/S.932 Mikaela Naylon Give Kids a Chance Act
---Implementation of ORPHAN Cures Act
---Pediatric Priority Review Voucher
---Cameron's Law

Pandemic Preparedness

Research & Development Tax Credit Reforms
---H.R.1: One Big Beautiful Bill Act
---Expensing of R&D Expenditures
---R&D Payroll Credit

Vaccines and Infectious Disease
---Countermeasure Injury Compensation Fund Amendment Act
---Let Injured Americans Be Legally Empowered (LIABLE) Act
---Vaccine Injury Compensation Modernization Act
---Vaccine Access Improvement Act

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), Commerce - Dept of (DOC)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code TRD

16. Specific lobbying issues

CFIUS and Foreign Investment

Drug Pricing
---CMMI: GLOBE and GUARD Models
---International Pricing Policies
---Most Favored Nation Drug Pricing Proposals
---Reference Pricing in Drug Reimbursement
---Tariffs

Foreign Agricultural Biotechnology Laws and Regulations
---China Biotechnology Regulations

Foreign Drug Data Protection Laws
---Implementation of BIOSECURE Act

Global Supply Chain Resiliency

Incentives for Domestic Manufacturing

Intellectual Property International Enforcement
---China

Synthetic Biotech
---S.3741: Biosecurity Modernization and Innovation Act of 2026

Tariffs

Trade Relations
---Section 232
---Genetic Resources, and Associated Traditional Knowledge
---World Intellectual Property Office (WIPO) - Treaty on Intellectual Property
---US-China IP Provisions

United Nations

World Trade Organization (WTO)
---TRIPS Waiver

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Commerce - Dept of (DOC), Office of Science & Technology Policy (OSTP), Office of the Vice President of the United States, U.S. Trade Representative (USTR), Natl Security Council (NSC)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

Information Update Page - Complete ONLY where registration information has changed.

20. Client new address

21. Client new principal place of business (if different than line 20)

22. New General description of client’s business or activities

LOBBYIST UPDATE

23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client

ISSUE UPDATE

24. General lobbying issue that no longer pertains

AFFILIATED ORGANIZATIONS

25. Add the following affiliated organization(s)

Internet Address:

26. Name of each previously reported organization that is no longer affiliated with the registrant or client

FOREIGN ENTITIES

27. Add the following foreign entities:

28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization

CONVICTIONS DISCLOSURE

29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery, extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
No Yes